Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN

NCT07390123 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

370

Enrollment

INDUSTRY

Sponsor class

Conditions

IgA Nephropathy (IgAN)

Interventions

DRUG: HSK39297
DRUG: Placebo

Sponsor

Haisco Pharmaceutical Group Co., Ltd.